Clinical Trends for May 2017

Ryan Syrek


May 26, 2017

Clinical Trend of the Week (May 13-19): Radicava

The first drug approval for a serious condition in many years resulted in this week’s top search term. Edaravone (Radicava, Mitsubishi Tanabe Pharma America) was approved by the US Food and Drug Administration (FDA) for use in patients with amyotrophic lateral sclerosis (ALS). The drug is a pyrazolone free-radical scavenger that is believed to lessen the effects of oxidative stress and is intended to slow down functional decline in patients with ALS. Edaravone represents the first new option in quite some time for doctors to offer patients with this degenerative condition. As this medication is incorporated into practice, and more information about its use is available, searches will remain popular.

For more information on ALS, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: